Get started
JACOBSON PHARMA CO LTDJJ

JACOBSON PHARMA CO LTD

1.19HKDD
+0.04+3.48%
At close at 08:08 GMT
HKD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

2633 fundamentals

Key facts

Market capitalization‪2.19 B‬HKD
Dividend yield (indicated)5.65%
Price to earnings Ratio (TTM)8.90
Basic EPS (TTM)0.13HKD
Founded2016
Employees (FY)‪1.72 K‬
CEOKwong Yip Sum
Websitejacobsonpharma.com
About

Jacobson Pharma Corp. Ltd. engages in the development, production, marketing, and sale of generic drugs. It operates through the Generic Drugs and Branded Healthcare segments. The Generic Drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. The Branded Healthcare segment develops, manufactures, and distributes branded medicines, proprietary Chinese medicines, and health and wellness products. The company was founded by Kwong Yip Sum on February 16, 2016 and is headquartered in Hong Kong.

Ownership
‪‪1.97 B‬‬
Closely held shares
‪‪1.59 B‬‬ (80.51%)
Free Float shares
‪‪384.84 M‬‬ (19.49%)
Closely held shares
‪‪1.59 B‬‬ (80.51%)
Free Float shares
‪‪384.84 M‬‬ (19.49%)
Capital structure
Market cap
‪‪2.19 B‬‬
Debt
‪‪699.85 M‬‬
Minority interest
‪‪24.22 M‬‬
Cash & equivalents
‪‪515.90 M‬‬
Enterprise value
‪‪2.39 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪2.19 B‬‬
Price to earning ratio (P/E)
8.90x
Price to sales ratio (P/S)
1.46x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
8.90x
Price to sales ratio (P/S)
1.46x
Valuation ratios
‪0.00‬
‪0.30‬
‪0.60‬
‪0.90‬
‪1.20‬
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪0.00‬
‪2.00‬
‪4.00‬
‪6.00‬
‪8.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪10.0%‬
‪12.1%‬
‪14.2%‬
‪16.3%‬
‪18.4%‬
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪0.00‬
‪‪250.00 M‬‬
‪‪500.00 M‬‬
‪‪750.00 M‬‬
‪‪1.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪210.00 M‬‬
‪‪420.00 M‬‬
‪‪630.00 M‬‬
‪‪840.00 M‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪210.00 M‬‬
‪‪420.00 M‬‬
‪‪630.00 M‬‬
‪‪840.00 M‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Generic Drugs
By country
Period: 2023
Hong Kong
China
Macau
Singapore

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
H2 '19
H1 '20
H1 '21
H2 '21
‪0.00‬
‪‪200.00 M‬‬
‪‪400.00 M‬‬
‪‪600.00 M‬‬
‪‪800.00 M‬‬
Actual
Estimate
Earnings
Next:Jun 19, 2025
H2 '19
H1 '20
H1 '21
H2 '21
‪0.00‬
‪0.01‬
‪0.02‬
‪0.03‬
‪0.04‬
Actual

Dividends

Dividend yield, history and sustainability

Dividend summary
50.31%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
5.65%
Last payment
0.035
Last ex-date
Feb 25, 2025
Dividend history
‪2%‬
‪4%‬
‪6%‬
‪8%‬
‪10%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.01‬
‪0.03‬
‪0.04‬
‪0.06‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '22
H2 '22
H1 '23
H2 '23
H1 '24
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪700.00 M‬‬
‪‪1.40 B‬‬
‪‪2.10 B‬‬
‪‪2.80 B‬‬
Assets
Liabilities